Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Li J, Menard V, Benish RL, Jurevic RJ, Guillemette C, Stoneking M, Zimmerman PA, Mehlotra RK.

Pharmacogenomics. 2012 Apr;13(5):555-70. doi: 10.2217/pgs.11.160.


CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH.

AIDS. 2009 Oct 23;23(16):2101-6. doi: 10.1097/QAD.0b013e3283319908.


High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.

Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C.

Pharmacogenet Genomics. 2013 Aug;23(8):415-27. doi: 10.1097/FPC.0b013e328363176f.


Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.

Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, Ueda N, Worku A, Haefeli WE, Lindquist L, Aderaye G, Burhenne J, Aklillu E.

J Antimicrob Chemother. 2011 Oct;66(10):2350-61. doi: 10.1093/jac/dkr304. Epub 2011 Aug 16.


Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.

Jamshidi Y, Moreton M, McKeown DA, Andrews S, Nithiyananthan T, Tinworth L, Holt DW, Sadiq ST.

J Antimicrob Chemother. 2010 Dec;65(12):2614-9. doi: 10.1093/jac/dkq369. Epub 2010 Oct 14.


Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.

Čolić A, Alessandrini M, Pepper MS.

Drug Metab Rev. 2015 May;47(2):111-23. doi: 10.3109/03602532.2014.982864. Epub 2014 Nov 13. Review.


CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.

Mehlotra RK, Bockarie MJ, Zimmerman PA.

Br J Clin Pharmacol. 2007 Sep;64(3):391-5. Epub 2007 Mar 28.


CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.

Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y.

Eur J Clin Pharmacol. 2012 Mar;68(3):267-71. doi: 10.1007/s00228-011-1118-0. Epub 2011 Sep 8.


Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH.

J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11.


Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.

Sarfo FS, Zhang Y, Egan D, Tetteh LA, Phillips R, Bedu-Addo G, Sarfo MA, Khoo S, Owen A, Chadwick DR.

J Antimicrob Chemother. 2014 Feb;69(2):491-9. doi: 10.1093/jac/dkt372. Epub 2013 Sep 29.


CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.

Powers V, Ward J, Gompels M.

HIV Med. 2009 Sep;10(8):520-3. doi: 10.1111/j.1468-1293.2009.00718.x. Epub 2009 May 21.


Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population.

Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, Oka S.

Drug Metab Dispos. 2009 Oct;37(10):1991-3. doi: 10.1124/dmd.109.027755. Epub 2009 Jul 6.


Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.

Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Aklillu E, Burhenne J.

PLoS One. 2013 Jul 5;8(7):e67946. doi: 10.1371/journal.pone.0067946. Print 2013.


Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.

Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, Zanger UM.

Pharmacogenet Genomics. 2005 Dec;15(12):861-73.


Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.

Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, Floyd M, Stein CM, Wilkinson GR.

J Infect Dis. 2009 Mar 15;199(6):872-80. doi: 10.1086/597125.


Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.

Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP.

J Antimicrob Chemother. 2010 Sep;65(9):1889-93. doi: 10.1093/jac/dkq260. Epub 2010 Jul 17.


Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.

Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V.

Pharmacogenomics. 2010 Sep;11(9):1223-34. doi: 10.2217/pgs.10.94.


Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans.

Svärd J, Spiers JP, Mulcahy F, Hennessy M.

J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):536-49. doi: 10.1097/QAI.0b013e3181f52f0c.


Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.

Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW.

Pharmacogenet Genomics. 2012 Dec;22(12):858-67. doi: 10.1097/FPC.0b013e32835a450b.

Supplemental Content

Support Center